#### 1 Supplemental oxygen costs and equipment utilization in a low-income population with ILD or 2 COPD 3 4 Kristopher P. Clark, MD<sup>1,2</sup>; Daniel J. Kass, MD<sup>1</sup>; Howard B. Degenholtz, PhD<sup>3</sup> 5 6 <sup>1</sup>The Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, University of 7 Pittsburgh, Department of Medicine, Division of Pulmonary, Allergy, Critical Care, and Sleep 8 Medicine, Pittsburgh, PA 9 <sup>2</sup>State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences, 10 Division of Pulmonary, Critical Care, and Sleep Medicine, Buffalo, NY <sup>3</sup>University of Pittsburgh, School of Public Health, Department of Health Policy and 11 12 Management, Pittsburgh, PA 13 14 ORCID IDs: 0009-0007-1034-9483 (K.P.C); 0000-0001-6597-7830 (D.J.K.); 0000-0003-1986-15 7360 (H.B.D.) 16 17 CORRESPONDING AUTHOR 18 Kristopher Clark, MD 19 SUNY at Buffalo Jacobs School of Medicine and Biomedical Sciences 20 **Buffalo General Medical Center** 21 100 High Street, Room B814 22 Buffalo, NY 14203 23 kclark4@buffalo.edu 24 25 AUTHORS' CONTRIBUTIONS: KPC, DJK, and HBD conceived and designed the study. KPC and 26 HBD obtained and analyzed the data. KPC, DJK, and HBD interpreted the data and drafted the 27 manuscript. 28 29 SOURCES OF SUPPORT: None 30 31 **WORD COUNT: 3,483**

### 33 ABSTRACT

- 34 **Rationale:** Supplemental oxygen is often prescribed to patients with interstitial lung disease
- 35 (ILD) and chronic obstructive pulmonary disease (COPD). The specific costs of oxygen therapy in
- 36 these diseases have not been fully described in patients living in the United States.
- 37 **Objectives:** Estimate Medicaid/Medicare costs for supplemental oxygen, characterize
- 38 differences in oxygen equipment utilization, and identify factors impacting the costs of
- 39 supplemental oxygen therapy in ILD and COPD.

40 Methods: We reviewed claims data for years 2016-2020 for Pennsylvania residents with ILD or

- 41 COPD who were dually eligible for Medicaid/Medicare and enrolled in traditional fee-for-service
- 42 Medicare. A generalized estimated equation (GEE) model was used to identify variables
- 43 associated with annual oxygen costs.

44 Measurements and Main Results: A greater proportion of paid claims in ILD were for oxygen

45 services (40.3% vs 22.0%) and for high flow oxygen (4.2% vs 2.2%), though ILD represented the

46 minority of paid oxygen claims (5.2%). Oxygen cost approximately \$65/month for both groups.

47 Most oxygen claims ( $\geq$ 94%) were for stationary concentrators. Liquid devices and stationary gas

48 were the least utilized equipment. Lower costs were associated with living in a competitive

49 bidding area and with markers of advanced age and worse health status.

50 **Conclusions:** Oxygen utilization is greater in ILD but is only a small portion of total oxygen claims

51 compared to COPD. Costs and equipment utilization were similar between groups. Liquid

52 oxygen claims were rare even among subjects requiring high flow. Oxygen therapy is common in

- 53 these diseases and likely represents a significant contribution to total healthcare costs.
- 54

## 55 ABSTRACT NUMBER OF WORDS: 249

- 57 KEY WORDS: Lung Diseases, Interstitial; Pulmonary Disease, Chronic Obstructive; Oxygen
- 58 Inhalation Therapy; Competitive Bidding; Health Care Costs

### 59 INTRODUCTION

60	In the United States, supplemental oxygen therapy is recommended for patients with chronic
61	obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) who have hypoxemia at
62	rest or with exertion(1). These recommendations are based primarily on studies of long-term
63	oxygen therapy (LTOT) which show improved mortality in patients with COPD(2,3). Oxygen
64	therapy is common in both diseases(4-7) and is associated with increased healthcare costs and
65	resource utilization(6,8-12). Healthcare spending on chronic respiratory diseases is estimated at
66	over \$100 billion per year(13,14); however, limited data exists on the costs associated with
67	oxygen therapy in ILD and COPD, and little is known about how these patients utilize oxygen
68	equipment or what factors contribute to oxygen costs in these diseases.
69	
70	Supplemental oxygen is delivered from stationary or portable compressed gas tanks, liquid
71	oxygen reservoirs/canisters, or oxygen concentrators. These devices differ in weight, ease of
72	use, capacity to provide high oxygen flow delivery, and cost(15). Patients with ILD and COPD are
73	often eligible for Medicare which provides coverage for durable medical equipment (DME)
74	services including supplemental oxygen equipment and supplies. The Centers for Medicare and
75	Medicaid Services (CMS) provides coverage for rented oxygen equipment/supplies including a
76	50% payment increase for equipment delivering >4 L/min(16,17). While the prescription of
77	oxygen therapy is determined by a medical provider, the type of equipment a patient receives is
78	often at the discretion of the locally contracted DME supplier. In 2011, CMS instituted a
79	competitive bidding program (CBP) designed to lower costs for oxygen and other DME(18,19).
80	While competitive bidding reduced DME spending(20-22), outside observers and patient

81	advocacy groups contend that these changes also resulted in a decrease in DME suppliers and		
82	impaired patients' access to supplemental oxygen services(23-25). This has prompted the		
83	drafting of the Supplemental Oxygen Access Reform (SOAR) Act which aims to improve oxygen		
84	access and payment structure(26).		
85			
86	We chose to study oxygen costs and utilization in patients who were dually eligible and		
87	receiving both Medicaid and Medicare fee-for-service (FFS) benefits as this represents		
88	vulnerable, low-income patients likely to have high disease burden. This also allowed us to focus		
89	on CMS policy regarding supplemental oxygen payments. We conducted this study of oxygen		
90	claims in dually eligible Pennsylvania residents with a diagnosis of ILD or COPD. Our objectives		
91	were to 1) estimate the costs for supplemental oxygen therapy, 2) characterize differences in		
92	utilization of oxygen delivery equipment, and 3) identify factors associated with increased costs		
93	of supplemental oxygen therapy in these diseases.		
94			
95	METHODS		
96	Data Source		
97	We reviewed Pennsylvania Medicare and Medicaid claims paid between January 1, 2016, and		
98	December 31, 2020. The data include beneficiary demographics and line-item DME claim		
99	payment amounts. Competitive bidding areas (CBA) were determined by matching beneficiary		
100	data to 2021 CBA zip codes(27) which were stable when compared to zip code data from earlier		
101	years (Supplement 1).		

# 103 Study Population

104	Subjects were dually eligible to receive both Medicaid and Medicare benefits for $\geq$ 1 month in a
105	calendar year. Subjects enrolled in Medicare Advantage or Special Needs Plans were excluded
106	since encounter data were not available. Subjects were required to have $\geq$ 2 outpatient or $\geq$ 1
107	inpatient claims associated with a diagnosis of ILD or COPD based on International Disease
108	Classification (ICD-10) coding (Supplement 2). ILD was defined by ICD J84 series which
109	represents fibrotic and interstitial diseases including idiopathic pulmonary fibrosis (IPF), the
110	most common form of ILD. COPD was defined using a validated coding algorithm developed by
111	the Chronic Condition Data Warehouse (CCW)(28). Subjects were excluded if they received
112	nursing home care or were non-Pennsylvania residents (Supplement 3).
113	
114	Supplemental Oxygen Use
115	Subjects were identified as oxygen users if they had $\geq 1$ paid claim in a calendar year associated
116	with a Healthcare Common Procedure Coding System (HCPCS) code for oxygen equipment
117	(Supplement 4). Claims were analyzed based on equipment type (compressed gas, liquid, or
118	concentrator), whether equipment was stationary or portable, and low versus high flow
119	delivery. We defined high flow as equipment coded for providing >4 L/min to align with CMS
120	reimbursement policy(16).
121	
122	Comorbidities
123	Comorbid conditions expected to be associated with supplemental oxygen use (tobacco use,
124	heart failure, pulmonary hypertension) were included in the model. To control for underlying

125	health status, we constructed a count of 27 other comorbid conditions based on the validated
126	set of algorithms (1999-2021) available from the CCW(28). See <b>Supplement 5</b> for definitions and
127	prevalence rates of comorbidities.
128	
129	Statistical Analyses
130	The primary outcome was total Medicare/Medicaid payments for oxygen equipment. Chi-
131	squared test at alpha=0.05 was used to compare median payment amounts. The total monthly
132	payment was calculated for each beneficiary using the total annual spending by both Medicaid
133	and Medicare divided by the number of months of eligibility that year. Annualized payments
134	were estimated by top/bottom-coding total monthly payment at the 95th-percentile to
135	eliminate outliers and multiplying by 12. Subcategories with fewer than 10 observations are
136	redacted.
137	
138	A generalized estimating equation (GEE) was estimated using the number of months of
139	eligibility per year as an offset term. This approach was chosen to account for repeated
140	observations of beneficiaries across multiple years. The model was adjusted for demographic

141 and other covariates described above. Beneficiaries with both ILD and COPD diagnoses were

included in the ILD cohort for all analyses. A sensitivity analysis was performed with these

subjects included in the COPD cohort. All analyses were performed using StataSE version 18.

144

This study was determined to be exempt from human subjects research by the InstitutionalReview Board at the University of Pittsburgh.

147

#### 148 **RESULTS**

- 149 A total of 2,297 unique beneficiaries with ILD and 72,412 with COPD were included in this study.
- 150 Baseline characteristics are reported using the first year each beneficiary appeared in the data
- 151 (**Table 1**). Mean (SD) age was 67.6 (14.0) for ILD and 64.5 (12.4) for COPD. A majority of subjects
- in both cohorts were female and non-Hispanic white. A majority of subjects in both cohorts
- were residents of non-rural areas and/or resided in a CBA. A total of 32.0% of ILD and 25.2% of
- 154 COPD beneficiaries were receiving home and community-based services. More than half of the
- beneficiaries in both cohorts had  $\geq$ 4 comorbidities. In the first year of study inclusion, a greater
- 156 proportion of beneficiaries with ILD compared to COPD had claims paid for any oxygen
- 157 equipment (34.5% vs 18.4%) and high flow oxygen (1.7% vs 0.5%).
- 158

159 The 2,297 ILD subjects had a total of 4,344 person-years during the study period (i.e., unique 160 beneficiary who met the inclusion criteria could appear in more than one calendar year); 40.3% 161 of person-years (1,752) had at least one claim for oxygen services. The 72,412 COPD subjects 162 had a total of 144,816 person-years during the study period; 22.0% of person-years (31,864) 163 had at least one claim for oxygen services. ILD subjects had a greater proportion of oxygen 164 claims across all five study years (Supplement 6). Of all person-year claims for oxygen services, a 165 greater proportion of ILD claims were coded high flow oxygen (4.2%) compared to COPD (2.2%). 166 Despite having a greater proportion of oxygen claims, ILD represented only 5.2% of all oxygen 167 claims and 9.0% of all high flow claims.

169	The total amount of oxygen payments made during the five-year study period was \$22,216,939
170	of which 76.5% (\$16,994,808) were made by Medicare. Of the total combined
171	Medicare/Medicaid payment amount during the study period, 5% (\$1,107,372) was for ILD and
172	95% (\$21,109,567) was for COPD. The median (IQR) monthly payment for all oxygen claims was
173	\$64.63 (\$35.04-\$94.56) for ILD and \$65.84 (\$33.63-\$96.70) for COPD (p-value=0.985). Median
174	monthly claim payments by calendar year ranged from \$59.57-\$74.11 for ILD and \$56.57-\$78.39
175	for COPD (Figure 1).
176	
177	At least 94% of paid oxygen claims in both cohorts included stationary oxygen concentrators. A
178	total of 69.2% of ILD and 62.8% of COPD claims included payments for portable gas cannisters
179	while 16.3% of ILD and 11.7% of COPD claims included payments for portable concentrators.
180	Less than 2.5% of claims in both cohorts included liquid oxygen (portable or stationary). A
181	similar utilization pattern was seen for claims coded for high flow delivery (Figure 2).
182	
183	Median monthly payments varied by equipment type and ranged from \$12.92-\$54.67 for ILD
184	and \$13.78-\$56.83 for COPD. For all paid claims and for high flow claims, the highest payment
185	was for stationary concentrators and the lowest payment was for portable gas. With the
186	exception of portable gas (p=0.020), there was no significant difference in median monthly
187	equipment payments between cohorts. In comparing payments for low vs high flow equipment,
188	high flow stationary concentrator payments were greater for COPD only (p-value <0.001). All
189	other equipment payments for high flow claims were not significantly different from low flow
190	claims ( <b>Table 2</b> )

191

192	A GEE model for repeated measures was performed to identify variables associated with higher			
193	annual oxygen payments among those with paid oxygen claims. As nearly all claims ( $\geq$ 94%) in			
194	both cohorts included stationary oxygen concentrators, we restricted the analysis to only these			
195	subjects and defined the dependent variable as the additional cost above and beyond that for a			
196	stationary concentrator. The model was adjusted for age, sex, race, residence in a non-metro			
197	area or CBA, long-term services and support use, diagnoses that may impact oxygen use			
198	(tobacco use, heart failure, pulmonary hypertension), count of other comorbidities, whether			
199	the oxygen claim was coded for high flow, and primary diagnosis (ILD vs COPD). Due to small			
200	sample sizes, we combined stationary and portable services for gas and liquid oxygen (e.g., gas			
201	stationary or portable, liquid stationary or portable).			

202

203 **Table 3a** shows the results of the GEE model. Of beneficiaries who had payments for stationary 204 concentrators, variables significantly associated with higher annual oxygen claim payments (p-205 value <0.05) included race other than Hispanic or non-Hispanic white or black, living in a non-206 metro location, having a diagnosis of heart failure, receiving gas or liquid oxygen or receiving 207 portable concentrators in addition to a stationary concentrator. Increasing age, receiving home-208 based care, residing in a CBA, current or prior tobacco use, and increasing number of 209 comorbidities were associated with lower annual oxygen claim payments. Increasing age and number of comorbidities were inversely related to payments for additional ambulatory oxygen 210 211 equipment. Sex, a diagnosis of pulmonary hypertension, whether the oxygen claim was coded 212 for high flow, and a diagnosis of ILD were not significantly associated with annual oxygen claim

213	payments. The cost of oxygen varied based on the combination of equipment that subjects
214	receive. Subjects who only received stationary concentrators had estimated annual costs of
215	\$964 for ILD and \$945 for COPD. Subjects who had both stationary concentrators and liquid
216	oxygen had an estimated annual cost \$1,164 for ILD and \$1,144 for COPD. The estimated annual
217	cost for subjects with a stationary oxygen concentrator and gas oxygen was \$1,027 for ILD and
218	\$1,008 for COPD. The estimated annual cost for subjects with both stationary and portable
219	oxygen concentrators was \$1,241 for ILD and \$1,222 for COPD ( <b>Table 3b</b> ).
220	
221	In a sensitivity analysis where beneficiaries with dual ILD and COPD diagnoses were included in
222	the COPD cohort, baseline characteristics and findings from the final GEE model were similar
223	with the exception being that there was no longer a significant difference in the number of
224	oxygen claims at baseline between cohorts (p-value=0.754) (Supplement 7).
224 225	oxygen claims at baseline between cohorts (p-value=0.754) ( <b>Supplement 7</b> ).
	oxygen claims at baseline between cohorts (p-value=0.754) (Supplement 7).
225	
225 226	DISCUSSION
225 226 227	DISCUSSION The results of our study demonstrate that among Pennsylvania residents dually eligible to
225 226 227 228	<b>DISCUSSION</b> The results of our study demonstrate that among Pennsylvania residents dually eligible to receive Medicare and Medicaid, a greater proportion of beneficiaries with ILD compared to
225 226 227 228 229	DISCUSSION The results of our study demonstrate that among Pennsylvania residents dually eligible to receive Medicare and Medicaid, a greater proportion of beneficiaries with ILD compared to COPD used supplemental oxygen and were more likely to have a high flow rate (>4 L/min);
225 226 227 228 229 230	<b>DISCUSSION</b> The results of our study demonstrate that among Pennsylvania residents dually eligible to receive Medicare and Medicaid, a greater proportion of beneficiaries with ILD compared to COPD used supplemental oxygen and were more likely to have a high flow rate (>4 L/min); however, COPD beneficiaries represented the vast majority (95%) of all paid oxygen claims. The
225 226 227 228 229 230 231	DISCUSSION The results of our study demonstrate that among Pennsylvania residents dually eligible to receive Medicare and Medicaid, a greater proportion of beneficiaries with ILD compared to COPD used supplemental oxygen and were more likely to have a high flow rate (>4 L/min); however, COPD beneficiaries represented the vast majority (95%) of all paid oxygen claims. The utilization of equipment other than oxygen concentrators was low in both groups even among

236	ILD and COPD are associated with high health care costs and health resource utilization(6,8-12).
237	In a study examining health care spending between 1996 and 2016, both ILD and COPD were
238	identified as being among the top 100 most expensive health conditions with spending in 2016
239	estimated at \$2.1 billion and \$34.3 billion respectively(13). While these estimates did not
240	include DME costs, other studies have found that DME use and specifically the use of
241	supplemental oxygen are also associated with increased healthcare costs and
242	utilization(6,11,12). Physician/DME services contribute an additional \$100 billion in
243	Medicare/Medicaid expenses each year(29). Our findings add to the existing literature by
244	providing estimates on the cost of oxygen services in ILD and COPD in low-income patients living
245	in the U.S.
246	
246 247	We also found that payments for specific oxygen delivery systems did not vary significantly
	We also found that payments for specific oxygen delivery systems did not vary significantly between ILD and COPD beneficiaries. We found that the vast majority of paid oxygen claims
247	
247 248	between ILD and COPD beneficiaries. We found that the vast majority of paid oxygen claims
247 248 249	between ILD and COPD beneficiaries. We found that the vast majority of paid oxygen claims (>94%) included stationary concentrators and that stationary concentrators were associated
247 248 249 250	between ILD and COPD beneficiaries. We found that the vast majority of paid oxygen claims (>94%) included stationary concentrators and that stationary concentrators were associated with the highest median monthly payment at approximately \$55-\$57. Our findings align with
247 248 249 250 251	between ILD and COPD beneficiaries. We found that the vast majority of paid oxygen claims (≥94%) included stationary concentrators and that stationary concentrators were associated with the highest median monthly payment at approximately \$55-\$57. Our findings align with those of a prior study of CMS DME claims from 2013-2019 which identified stationary oxygen
247 248 249 250 251 252	between ILD and COPD beneficiaries. We found that the vast majority of paid oxygen claims (≥94%) included stationary concentrators and that stationary concentrators were associated with the highest median monthly payment at approximately \$55-\$57. Our findings align with those of a prior study of CMS DME claims from 2013-2019 which identified stationary oxygen concentrators as the highest volume respiratory DME product, utilized by 2.32% of all Medicare
247 248 249 250 251 252 253	between ILD and COPD beneficiaries. We found that the vast majority of paid oxygen claims ( $\geq$ 94%) included stationary concentrators and that stationary concentrators were associated with the highest median monthly payment at approximately \$55-\$57. Our findings align with those of a prior study of CMS DME claims from 2013-2019 which identified stationary oxygen concentrators as the highest volume respiratory DME product, utilized by 2.32% of all Medicare beneficiaries in 2019(30). Both this study and our study identified low utilization rates for other

257	that liquid oxygen utilization rates are low due to decreased availability of this device,
258	potentially as a result of CMS's competitive bidding program (CBP). Our estimated monthly
259	median costs differ from those found in a recent review of supplemental oxygen spending in
260	Medicare beneficiaries with COPD which estimated monthly mean costs ranging between \$687
261	to \$771(22). This may be due to different methodologies in cost estimation and which payments
262	were included. Our study focused only on payments made by Medicaid/Medicare and did not
263	include other insurance payments or beneficiary out-of-pocket expenses.
264	
265	As previously noted, CMS implemented the CBP in 2011 as a measure to decrease CMS
266	expenditures and beneficiary out-of-pocket expenses on selected DME with high utilization
267	rates and high costs(18). Oxygen equipment is one of the most frequently prescribed DME and
268	is included in the CBP(31). Our model found that living in a CBA was associated with lower
269	oxygen costs, consistent with reports by CMS and other government agencies that the CBP
270	lowered costs of DME(31-33). These agencies also report that the CBP has not negatively
271	impacted clinical outcomes or disrupted DME supply, assertions that were also noted in a recent
272	review of early CBP oxygen claims data in patients with COPD(22). However, numerous outside
273	observers including researchers and advocacy groups have raised concerns that the CBP has
274	resulted in a decreased number of DME suppliers and disrupted access to DME services
275	including liquid oxygen(23-25,34). It has been reported that the number of DME suppliers
276	contracted by CMS to provide oxygen equipment has decreased over time and that the
277	percentage of beneficiaries using oxygen DME has also decreased with the greatest change seen
278	with stationary (-89%) and portable (-86%) liquid oxygen devices(30). The reduction in liquid

279 oxygen utilization has raised concerns that the CBP resulted in more limited access to this 280 therapy(23-25,35). Liquid oxygen is considered to be a more ideal delivery method for patients 281 who require high flow rates due to its lighter weight and longer duration of use with higher flows compared to compressed gas tanks; however, it is likely more costly for DME suppliers to 282 283 maintain and deliver this form of oxygen therapy which may limit its availability. While many 284 stationary concentrators can meet high flow demands, portable oxygen concentrators currently 285 can not. This limits the portable oxygen options for patients requiring higher flow. The reduced 286 availability and utilization of portable liquid oxygen may have negative impacts on patients' 287 mobility and quality of life. These concerns have led to the drafting of the Supplemental Oxygen 288 Access Reform (SOAR) Act which aims to improve oxygen access and change how oxygen 289 equipment is reimbursed(26). While we did not compare oxygen costs or utilization over time 290 or to pre-competitive bidding data, our findings, which included both COPD and ILD diagnoses, 291 suggest that there are limitations in oxygen equipment utilization, at least among low-income 292 patients including those who require high flow oxygen. It is possible these limitations resulted 293 from changes implemented by the CBP.

294

In addition to living in a CBA, we also found that advanced age and increased number of
 comorbidities were associated with reduced oxygen payments. Further analysis revealed that
 these findings were primarily related to reduced payment for portable oxygen devices. Whether
 this means that older and sicker patients are less mobile or less likely to undergo ambulatory
 oxygen assessments is not known. Lastly, current or prior tobacco use was associated with a

lower cost, possibly due to prescribers withholding oxygen prescriptions to patients who
 actively smoke due to increased risk of fire and injury.

302

303 Increased oxygen costs were associated with living in a non-metro area. Greater than 98% of 304 non-metro claims are excluded from a CBA. We also found that non-Hispanic black and non-305 Hispanic, non-white or non-black race were associated with higher costs compared to non-306 Hispanic whites. Both of these race/ethnic groups had a greater proportion of beneficiaries 307 residing within CBAs compared non-Hispanic whites. Racial and ethnic minorities have been 308 shown to bear a disproportionate economic burden related to healthcare costs secondary to 309 inequities in disease burden, morbidity, and premature death(36). Such inequities may also be 310 found in oxygen equipment utilization as well which may account for this finding. Future studies 311 should further explore the impact race/ethnicity, income, and education have on oxygen 312 utilization. 313 314 A diagnosis of heart failure was also associated with increased costs while pulmonary 315 hypertension was not. Pulmonary hypertension is often associated with oxygen needs and may

be more common in patients with ILD(37,38). It is possible that our study was underpowered to

detect the true effect of this comorbidity. Lastly, while CMS provides 50% increased payment to

318 claims coded for providing high flow (>4 L/min)(17), with the exception of stationary

319 concentrators for COPD, we did not find that payments for high flow claims were significantly

320 greater than claims for  $\leq 4$  L/min. It may be that our study was underpowered to detect such

321 differences given the low number of high flow claims in our dataset.

323	Our study has several strengths. To our knowledge, we are the first study to quantify the cost of
324	oxygen spending in ILD in the U.S. and compare these costs to COPD. We were able to maximize
325	our sample size by using claims data across five years which allowed us to not only quantify the
326	use and cost of oxygen but to assess the impact other parameters have on oxygen costs. By
327	focusing the study on dually eligible beneficiaries, we were able to estimate actual Medicare
328	and Medicaid expenses for oxygen supplies for a vulnerable and policy-relevant population.
329	
330	Our study also has several limitations. Our results may not be generalizable to beneficiaries
331	receiving other Medicare or Medicaid services, those with substantial out-of-pocket expenses,
332	or those who have oxygen services paid through private insurance carriers. Results may not be
333	generalizable to patients living in other states; however, Pennsylvania is a large state with both
334	large metropolitan areas and large rural areas and is demographically similar to the US average.
335	Nevertheless, recent data from our center suggest that regional differences in air quality may
336	adversely impact the prognosis of pulmonary fibrosis(39), thus oxygen utilization may have
337	regional variation due to these exacerbating factors. Due to increased enrollment in Medicare
338	Advantage plans over the course of our study, our data had a decreasing number of dually
339	eligible individuals over time. We also did not calculate how oxygen costs compare to total DME
340	expenditures or total Medicare and Medicaid spending. Future studies should examine the cost
341	of oxygen in other populations including privately insured individuals and in national claims
342	databases.


344	While our study identified payments made for oxygen claims, we were unable to determine
345	whether oxygen prescriptions were appropriate or whether beneficiaries utilized these oxygen
346	services. Lastly, our small sample of beneficiaries with high flow claims, especially among
347	subjects with ILD, limits our ability to estimate oxygen costs and utilization for these subjects,
348	though it does appear that, for some oxygen equipment, payments are not being increased as
349	per CMS policy. Future studies and investigations are needed to further explore this finding.
350	
351	CONCLUSION
352	The vast majority of supplemental oxygen claims for Pennsylvania residents dually eligible for
353	Medicaid and Medicare fee-for-service benefits with diagnoses of ILD or COPD were for
354	stationary oxygen concentrators. Subjects with ILD had a greater proportion of paid oxygen
355	claims but represent only a small portion of all oxygen claims. Among users of oxygen
356	concentrators, the addition of liquid oxygen further increases costs compared to gas equipment,
357	however the utilization of liquid oxygen is low in both diseases. Our findings support the
358	concerns raised by other studies that the CMS competitive bidding program may have resulted
359	in decreased access for liquid oxygen services.
360	

## 361 ACKNOWLEDGEMENTS


362 Jie Lin, PhD 363

# Table 1. Demographic and clinical characteristics of unique individuals at time of first year in the dataset (2016-2020)

	ILD (n=2,297)	COPD (n=72,412)
Age, mean (SD)	67.6 (14.0)	64.5 (12.4)
Male, N (%)	901 (39.2)	29,574 (40.8)
Race/Ethnicity, N (%)		
Non-Hispanic White	1,392 (60.6)	51,578 (71.2)
Non-Hispanic Black	420 (18.3)	13,226 (18.3)
Hispanic	218 (9.5)	3,673 (5.1)
Other	267 (11.6)	3,935 (5.4)
Home and community-based services	734 (32.0)	18,269 (25.2)
Months with an oxygen claim, median (IQR)	11 (5-12)	12 (6-12)
Non-metro resident, N (%)	330 (14.4)	13,999 (19.3)
Competitive bidding area resident, N (%)	1,489 (64.8)	42,546 (58.8)
Confounders of oxygen use, N (%)		
Current or prior tobacco use	600 (26.1)	30,235 (41.8)
Heart failure	987 (43.0)	21,252 (29.4)
Pulmonary hypertension	457 (19.9)	5,526 (7.6)
Count of other comorbidities, N (%)		
0 to 1	164 (7.1)	8,243 (11.4)
2 to 3	383 (16.7)	17,342 (24.0)
4 to 5	576 (25.1)	19,141 (26.4)
6 to 7	580 (25.3)	15,190 (21.0)
8 to 9	390 (17.0)	8,886 (12.3)
10 or more	204 (8.9)	3,610 (5.0)
Any Oxygen Claim, N (%)	792 (34.5)	13,300 (18.4)
High Flow (>4 L/min) Oxygen Claim, N (%)	37 (1.7)	329 (0.5)



# 367 Figure 1. Median (IQR) monthly payment for oxygen claims by year



#### 370 Figure 2. Proportion of person-years claims by equipment type

# Table 2. Median (IQR) monthly payment for person-year claims by oxygen equipment type

# 375 and flow rate

Equipment	ILD				COPD			
Туре	All claims	>4 L/min claims	<u>&lt;</u> 4 L/min claims	p-value*	All claims	>4 L/min claims	<u>&lt;</u> 4 L/min claims	p-value*
	\$54.67	\$55.03	\$54.67	0.597	\$56.83	\$61.61	\$56.74	<0.001
Stationary concentrator	(\$29.62- \$74.27)	(\$30.20- \$72.03)	(\$29.55- \$74.53)		(\$29.55- \$80.00)	(\$35.89- \$86.16)	(\$29.19- \$79.78)	
	\$21.20	\$22.21	\$21.08	0.806	\$22.77	\$19.37	\$22.79	0.28
Portable concentrator	(\$11.72- \$28.96)	(\$12.88- \$25.32)	(\$11.35- \$29.19)		(\$11.41- \$29.01)	(\$9.54- \$29.99)	(\$11.42- \$29.01)	
	\$12.92	\$12.56	\$12.96	0.113	\$13.78	\$14.02	\$13.78	0.452
Portable gas	(\$6.64-\$21.92)	(\$6.60- \$21.20)	(\$6.65- \$22.01)		(\$7.53- \$22.38)	(\$8.58- \$23.57)	(\$7.51- \$22.36)	
	\$16.62		\$20.18		\$18.83	\$19.28	\$18.82	0.143
Portable liquid	(\$7.77-\$31.27)		(\$9.90- \$31.69)		(\$11.59- \$32.96)	(\$10.13- \$29.51)	(\$11.59- \$32.99)	
Stationary gas								
	\$43.05		\$37.33		\$45.22		\$45.22	
Stationary liquid	(\$29.52- \$59.99)		(\$24.63- \$59.75)		(\$30.72- \$69.02)		(\$31.16- \$68.73)	

376 \*p-value compares median payment between >4 L/min and <4 L/min claims

377 Note: cells with <10 observations are redacted

## 379 Table 3. Results of GEE model

380

# 381Table 3a. Results of a GEE model for repeated measures assessing factors influencing oxygen

# 382 payments among beneficiaries who had claims paid for stationary oxygen concentrators

Variable	Coefficient	95% CI	p-value
Age	-45.52	-54.51, -36.53	<0.001
Male	7.14	-10.71, 25.00	0.433
Race/ethnicity <sup>1</sup>			
Non-Hispanic black	26.18	0.51, 51.85	0.046
Hispanic	-13.93	-61.53, 33.68	0.566
Other	49.91	7.20, 92.62	0.022
Non-metro	153.47	129.99, 176.96	<0.001
Competitive bidding area	-65.67	-86.61, -44.74	<0.001
Home and community- based services <sup>2</sup>	-93.51	-110.78, -76.24	<0.001
Comorbidity count <sup>3</sup>		·	
2-3	-100.96	-138.45, -63.46	<0.001
4-5	-151.61	-188.22, -115.00	<0.001
6-7	-214.11	-251.07, -177.15	<0.001
8-9	-287.32	-325.82, -248.82	<0.001
10 or more	-327.00	-369.52, -284.48	<0.001
Current or prior tobacco use	-48.69	-66.76, -30.62	<0.001
Heart failure	44.35	25.82, 62.88	<0.001
Pulmonary hypertension	8.79	-13.24, 30.82	0.434
Gas oxygen (portable or stationary)	176.28	159.03, 193.53	<0.001
Liquid oxygen (portable or stationary)	200.48	70.23, 330.72	0.003
Portable oxygen concentrator	317.92	291.85, 343.99	<0.001
High flow (>4 L/min)	28.76	-18.15, 75.67	0.230
ILD diagnosis	19.27	-19.35, 57.89	0.328
_cons	984.08	945.93, 1022.24	<0.001

383

3 <sup>1</sup>Reference group = non-Hispanic white

384 <sup>2</sup>Reference group = 0-1 comorbidity

385 <sup>3</sup>Reference group = No home or community-based services

#### Table 3b. Estimated annual costs of oxygen equipment based on GEE model

Oxygen Equipment	ILD Annual Cost	COPD Annual Cost	
	(95% CI)	(95% CI)	
Stationary concentrator only	\$964.36	\$945.09	
	(\$926.59 <i>,</i> \$1022.13)	(\$936.76, \$953.41)	
Stationary concentrator + Gas (Portable/Stationary)	\$1027.27	\$1008.00	
	(\$989.06 <i>,</i> \$1065.48)	(\$997.26, \$1018.74)	
Stationary concentrator + Liquid	\$1163.92	\$1144.65	
(Portable/Stationary)	(\$1029.19 <i>,</i> \$1298.64)	(\$1014.60, \$1274.69)	
Stationary concentrator + Portable Concentrator	\$1241.31	\$1222.04	
	(\$1198.25 <i>,</i> \$1284.37)	(\$1197.29, \$1246.79)	

### **REFERENCES**

390	1.	Jacobs SS, Krishnan JA, Lederer DJ, Ghazipura M, Hossain T, Tan AM, et al. Home oxygen
391		therapy for adults with chronic lung disease. An official American Thoracic Society
392		clinical practice guideline. Am J Respir Crit Care Med 2020;202(10):e121-e141.
393	2.	Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease:
394		a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980;93(3):391-
395		398.
396	3.	Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating
397		chronic bronchitis and emphysema. Report of the Medical Research Council Working
398		Party. Lancet 1981;1(8222):681-686.
399	4.	Khor YH, Renzoni EA, Visca D, McDonald CF, Goh NSL. Oxygen therapy in COPD and
400		interstitial lung disease: navigating the knowns and unknowns. ERJ Open Res 2019;5(3).
401	5.	Wang BR, Edwards R, Freiheit EA, Ma Y, Burg C, de Andrade J, et al. The Pulmonary
402		Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. Ann Am Thorac
403		Soc 2020;17(12):1620-1628.
404	6.	Ke X, Marvel J, Yu TC, Wertz D, Geremakis C, Wang L, et al. Impact of lung function on
405		exacerbations, health care utilization, and costs among patients with COPD. Int J Chron
406		Obstruct Pulmon Dis 2016;11:1689-1703.
407	7.	Wallace A.E. KS, Bayer V., Shaikh A., Shinde M.U., Willey VJ, Napier MB, Singer JR. Health
408		care resource utilization and exacerbation rates in patients with COPD stratified by
409		disease severity in a commercially insured population. Journal of Managed Care and
410		Specialty Pharmacy 2019;25(2):205-217.

411

8.

Stephenson JJ, Wertz D, Gu T, Patel J, Dalal AA. Clinical and economic burden of dyspnea

412		and other COPD symptoms in a managed care setting. Int J Chron Obstruct Pulmon Dis
413		2017;12:1947-1959.
414	9.	Wu N, Yu YF, Chuang CC, Wang R, Benjamin NN, Coultas DB. Healthcare resource
415		utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United
416		States. J Med Econ 2015;18(4):249-257.
417	10.	Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E. Burden
418		of illness in idiopathic pulmonary fibrosis. J Med Econ 2012;15(5):829-835.
419	11.	Collard HR, Chen SY, Yeh WS, Li Q, Lee YC, Wang A, et al. Health care utilization and costs
420		of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older.
421		Ann Am Thorac Soc 2015;12(7):981-987.
422	12.	Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic Burden of Chronic
423		Obstructive Pulmonary Disease (COPD): A Systematic Literature Review. Int J Chron
424		Obstruct Pulmon Dis 2020;15:439-460.
425	13.	Dieleman JL, Cao J, Chapin A, Chen C, Li Z, Liu A, et al. US Health Care Spending by Payer
426		and Health Condition, 1996-2016. JAMA 2020;323(9):863-884.
427	14.	Duan KI, Birger M, Au DH, Spece LJ, Feemster LC, Dieleman JL. Health Care Spending on
428		Respiratory Diseases in the United States, 1996-2016. Am J Respir Crit Care Med
429		2023;207(2):183-192.
430	15.	Hardavella G, Karampinis I, Frille A, Sreter K, Rousalova I. Oxygen devices and delivery
431		systems. Breathe (Sheff) 2019;15(3):e108-e116.

- 432 16. Centers for Medicaid and Medicare Services (cms.gov). Article Oxygen and oxygen
- 433 equipment policy article (A5214) [Internet]. Baltimore (MD): Centers for Medicare and
- 434 Medicaid Services; 2023 [updated April 1, 2023; accessed November 18, 2024]. Available
- 435 from: <u>https://www.cms.gov/medicare-coverage-</u>
- 436 database/view/article.aspx?articleid=52514&ver=61&LCDId=33797&Date=&DocID=L337
- 437 <u>97&bc=hAAAAAgAEAAAAAAA&</u>=.
- 438 17. Centers for Medicaid and Medicare Services (cms.gov). Medicare Claims Processing
- 439 Manual chapter 20 durable medical equipment, prosthetics, orthotics, and supplies
- 440 (DMEPOS) [Internet]. Rev 12557. Baltimore (MD): Centers for Medicare and Medicaid
- 441 Services; 2022 [updated March 28, 2024; accessed November 18, 2024]. Available from:
- 442 https://www.cms.gov/Regultions-and-
- 443 <u>Guidance/Guidance/Manuals/Downloads/clm104c20.pdf</u>.
- 18. Centers for Medicaid and Medicare Services (cms.gov). DMEPOS Competitive Bidding -
- 445 Home [Internet]. Baltimore (MD): Centers for Medicare and Medicaid Services; [updated
- 446 September 10, 2024; accessed November 18, 2024]. Available from:
- 447 <u>https://www.cms.gov/Medicare/Medicare-Fee-for-Service-</u>
- 448 <u>Payment/DMEPOSCompetitiveBid</u>.
- 449 19. Medicare Payment Advisory Commission (medpac.gov). MedPAC Payment Basics
- 450 Durable Medical Equipment Payment Systems [Internet]. Washington (DC): Medicare
- 451 Payment Advisory Commission (MedPAC); 2022 [updated October 2022; accessed
- 452 December 31, 2022]. Available from: <u>https://www.medpac.gov/wp-</u>
- 453 content/uploads/2021/11/MedPAC Payment Basics 22 DME FINAL SEC.pdf.

- 454 20. Medicare Payment Advisory Commission (medpac.gov). June 2018 Report to the
- 455 Congress: Medicare and the Health Care Delivery System [internet]. Washington, DC:
- 456 [accessed Jan 2, 2023]. Available from: <u>https://www.medpac.gov/document/http-www-</u>
- 457 <u>medpac-gov-docs-default-source-reports-</u>
- 458 jun18\_medpacreporttocongress\_rev\_nov2019\_note\_sec-pdf/.
- 459 21. Newman D, Barrette E, McGraves-Lloyd K. Medicare Competitive Bidding Program
- 460 Realized Price Savings For Durable Medical Equipment Purchases. Health Aff (Millwood)
- 461 2017;36(8):1367-1375.
- 462 22. Duan KI, Obara E, Wong ES, Liao JM, Sabbatini AK, Donovan LM, et al. Supplemental
- 463 Oxygen Use, Outcomes, and Spending in Patients With COPD in the Medicare
- 464 Competitive Bidding Program. JAMA Intern Med 2024.
- 465 23. Jacobs SS, Lindell KO, Collins EG, Garvey CM, Hernandez C, McLaughlin S, et al. Patient
- 466 perceptions of the adequacy of supplemental oxygen therapy. Results of the American
- 467 Thoracic Society Nursing Assembly Oxygen Working Group Survey. Ann Am Thorac Soc
- 468 2018;15(1):24-32.
- 469 24. Lindell KO, Collins EG, Catanzarite L, Garvey CM, Hernandez C, McLaughlin S, et al.
- 470 Equipment, access and worry about running short of oxygen: Key concerns in the ATS
- 471 patient supplemental oxygen survey. Heart Lung 2019;48(3):245-249.
- 472 25. Dobson A HS, Kilby D, Hu J, DaVanzo JE. Access to home medical equipment: survey of
- 473 beneficiary, case manager, and supplier experiences: understanding the impact of
- 474 competitive bidding. August 30, 2023 October 2017.

- 475 26. SOAR Act of 2024, S 3821, 118th Cong (2023-2024). [accessed November 15, 2024].
- 476 Available from: https://www.congress.gov/bill/118th-congress/senate-bill/3821.
- 477 27. Centers for Medicaid and Medicare Services. 2021 DMEPOS Competitive Bidding Areas.
- 478 [accessed April 20, 2023]. Available from:
- 479 <u>https://www.dmecompetitivebid.com/cbic/cbicr2021.nsf/DocsCat/H5O2KFK4HO.</u>
- 480 28. Chronic Conditions Data Warehouse. [accessed September 5, 2022]. Available from:
- 481 https://www2.ccwdata.org/web/guest/condition-categories-chronic.
- 482 29. Centers for Medicaid and Medicare Services (cms.gov). CMS Fast Facts. 2023 [updated
- 483 March 2024; accessed November 18, 2024]. Available from: <u>https://data.cms.gov/fact-</u>
- 484 <u>sheet/cms-fast-facts</u>.
- 485 30. Duan KI, Wong ES, Liao JM, Sabbatini AK, Au DH. Long-term trends in home respiratory
- 486 medical equipment among U.S. Medicare patients, 2013-2019. Am J Respir Crit Care
- 487 Med 2022;206(4):509-511.
- 488 31. Ding H. DM, Starc A. Getting the price right? The impact of competitive bidding in the
  489 Medicare program. July 30, 2022 2021.
- 490 32. Department of Health and Human Services OolG. Round 2 Competitive Bidding for
- 491 Oxygen: Continued Access for Vast Majority of Beneficiaries. May 2018 2018.
- 492 33. Cavanaugh S. Providing quality, affordable durable medical equipment for beneficiariees.
- 493 Centers for Medicare and Medicaid Servcies; 2016 [updated July 1, 2016; accessed
- 494 Available from: <u>https://wayback.archive-</u>
- 495 <u>it.org/2744/20161207130006/https:/blog.cms.gov/2016/05/17/providing-quality-</u>
- 496 affordable-durable-medical-equipment-for-beneficiaries/.

- 497 34. American Association for Respiratory Care/American Lung Association/American
- 498 Thoracic Society (lung.org). Partners Oxygen Policy Brief: Request: Address Needed
- 499 Reforms in CMS Reimbursement for Supplemental Oxygen [Internet]. [updated August 8,
- 500 2021; accessed May 26, 2023]. Available from:
- 501 https://www.lung.org/getmedia/209550fe-d52b-4a7a-8385-5cbf822f59b4/partners-
- 502 <u>oxygen-policy-brief-28aug21.pdf</u>.
- 503 35. Jacobs SS, Lederer DJ, Garvey CM, Hernandez C, Lindell KO, McLaughlin S, et al.
- 504 Optimizing home oxygen therapy. An official American Thoracic Society Workshop
- 505 Report. Ann Am Thorac Soc 2018;15(12):1369-1381.
- 506 36. LaVeist TA, Perez-Stable EJ, Richard P, Anderson A, Isaac LA, Santiago R, et al. The
- 507 Economic Burden of Racial, Ethnic, and Educational Health Inequities in the US. JAMA
- 508 2023;329(19):1682-1692.
- 509 37. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. Pulmonary
- 510 hypertension in chronic lung disease and hypoxia. Eur Respir J 2019;53(1).
- 511 38. Nathan SD, Barnett SD, King CS, Provencher S, Barbera JA, Pastre J, et al. Impact of the
- new definition for pulmonary hypertension in patients with lung disease: an analysis of
- 513 the United Network for Organ Sharing database. Pulm Circ
- 514 2021;11(2):2045894021999960.
- 515 39. Goobie GC, Carlsten C, Johannson KA, Khalil N, Marcoux V, Assayag D, et al. Association
- 516 of Particulate Matter Exposure With Lung Function and Mortality Among Patients With
- 517 Fibrotic Interstitial Lung Disease. JAMA Intern Med 2022;182(12):1248-1259.
- 518